CytomX Therapeutics CTMX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's total liabilities & equity?
- CytomX Therapeutics (CTMX) reported total liabilities & equity of $359.36M in Q1 2026.
- How has CytomX Therapeutics's total liabilities & equity changed year-over-year?
- CytomX Therapeutics's total liabilities & equity increased by 264.8% year-over-year, from $98.5M to $359.36M.
- What is the long-term trend for CytomX Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total liabilities & equity has grown at a -15.8% compound annual growth rate (CAGR), from $358.66M to $151.57M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.